British multinational pharma company Zeneca was formed by a demerger of the pharmaceuticals and agrochemicals businesses of Imperial Chemical Industries in The name Zeneca was invented by a branding consultancy who had been instructed by its chief executive, Sir David Barnes, to find a name which was memorable, had no associations with other companies, nor was offensive in any language.
In , Zeneca decided to sell its Zeneca Specialities division, which included activities in biocides, industrial colours, lifescience modules, performance and intermediate chemicals. It was this decision that fuelled many rumours that Zeneca was preparing to merge with another company. These rumours turned out to be true when the Astra and Zeneca merger was announced in December of the same year.
On completion of the merger, Astra Shareholders held a In August , Nexium esomeprazole for the treatment of acid-related diseases, such as gastrooesophageal reflux disease GERD , was first launched in Sweden. The same year, AZ also entered into its third collaboration agreement with Astex Therapeutics, this time to develop small-molecule protein kinase B PKB to further contribute in the fight against cancer. However many analysts felt the company had paid far too much for the US-based company, especially as it had few late-stage drugs with major commercial potential.
Having already acquired UK-based Cambridge Antibody Technology in , AstraZeneca merged these two companies to create a dedicated global biologics organisation known as MedImmune. Bestseller Nexium had become available in approximately markets over the past seven years since launch. Over 85, patients in 62 countries were evaluated in clinical trials of Nexium and close to million patient treatments were administered by the end of Since , AstraZeneca found itself in various disputes over generic versions of Nexium, which has patents due to expire in In April , AstraZeneca also reached an agreement with Ranbaxy, an Indian generic drugmaker, allowing it to produce a generic version of Nexium starting in May Arrow Therapeutics focused exclusively on novel antiviral drug discovery and development, including several different approaches towards Hepatitis C and Respiratory Syncytial Virus RSV.
It was around this point that AZ decided to re-focus its disease area research with infection and anti-bacterials as one of its key therapy areas. Learn more about us. About Us We push the boundaries of science to deliver life-changing medicines. Learn more on our global site. Contact Us If you are in the United States and would like additional information regarding AstraZeneca products, or you are a third party with an offer of services for AstraZeneca, you can contact the AstraZeneca Information Center by phone at Monday - Friday 8 a.
More info. US leadership team. Ruud Dobber, Ph. Rachele Berria, MD Ph. View careers. Learn more. You are now leaving AstraZeneca-us. Cancel Continue. I disagree I agree. Business Today Monday to Friday See a sample. Get the latest business news and commentary from our expert business team every weekday. Sign up. Sign In. Don't have an account? Forgot Password? Not an Irish Times subscriber?
0コメント